Recent Quotes (30 days)

You have no recent quotes
chg | %

Knight Therapeutics Inc  

(Public, CVE:GUD)   Watch this stock  
Find more results for GUD
6.14
Apr 28 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 3.51 - 7.24
Open     -
Vol / Avg. 0.00/822,875.00
Mkt cap 138.83M
P/E     -
Div/yield     -
EPS 0.00
Shares     -
Beta     -
Inst. own     -
Nov 9, 2016
Q3 2016 Knight Therapeutics Inc Earnings Call
Nov 9, 2016
Q3 2016 Knight Therapeutics Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 301.16% 3294.79%
Operating margin 389.96% 3569.53%
EBITD margin - -865.38%
Return on average assets 2.62% 6.02%
Return on average equity 2.64% 6.10%
Employees 14 -
CDP Score - -

Address

376 Victoria Ave Suite 220
WESTMOUNT, QC H3Z 1C3
Canada
+1-514-4844483 (Phone)
+1-514-4814116 (Fax)

Website links

Description

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.